Market Overview

Certain factors that are driving the market growth include rising adoption and approval of new treatment techniques, a growing number of government initiatives and funding.

The worldwide incidence of hemophilia is not well known but estimated at more than 400,000 people. Approximately 75% of people with hemophilia around the world still receive inadequate treatment or have no access to treatment. Scientists report that hemophilia is three times more prevalent in men worldwide than previously thought and still associated with a poorer life expectancy, especially in low-income countries. Findings of the study, “Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries,” were published in the Annals of Internal Medicine. This observational study came in response to a call by the World Federation of Hemophilia to more accurately measure the disease’s prevalence and its impact on life expectancy.

Scope of the Report

Hemophilia is a genetic bleeding disorder that prevents the blood from clotting normally. The primary symptom is uncontrolled, often spontaneous bleeding in different areas of the body. The deficiency of fibrinogen, prothrombin, factor V (FV), FVII, FVIII, FIX, FX, FXI, and FXIII, called rare coagulation disorders (RCDs), may result in coagulopathies leading to spontaneous or posttrauma and postsurgery hemorrhages.

Key Market Trends

Fresh frozen plasma (FFP) is Expected to Hold Significant Market Share in the Treatment Segment

Plasma transfusion is indicated for the management of bleeding or to prevent bleeding prior to an urgent invasive procedure in patients requiring replacement of multiple coagulation factors. Fresh frozen plasma is the fluid portion of a unit of whole blood that is frozen in a designated time frame, usually within 8 hours. FFP contains all coagulation factors except platelets. FFP contains fibrinogen (400 to 900 mg/unit), albumin, protein C, protein S, antithrombin, tissue factor pathway inhibitor. FFP can only be administered intravenously. FFP must be ABO compatible with the recipient’s red cells. The FFP container and fluid upon visual inspection should have no leakage, clots, or abnormal color.

North America Dominates the Market and Expected to do Same in the Forecast Period

According to the Center for Disease Control and Prevention (CDC), Hemophilia A occurs in 1 in 5,000 live male births. Hemophilia A is about four times as common as hemophilia B. The number of people with hemophilia in the United States is estimated to be about 20,000 individuals (National Hemophilia Foundation, 2018). In the United States, most people with hemophilia are diagnosed at a very young age. Based on CDC data, the median age at diagnosis is 36 months for people with mild hemophilia, 8 months for those with moderate hemophilia, and 1 month for those with severe hemophilia. In about two-thirds of cases, there is a family history of hemophilia. The diagnosis of hemophilia is made using a special blood test and most babies can be tested soon after birth. Sometimes prenatal genetic testing is done to diagnose hemophilia before birth (CDC, 2019).

Competitive Landscape

The global Rare Hemophilia Factors market is moderately competitive and consists of a number of major players. Companies like Baxter Healthcare, Bayer Healthcare, Bio Products Laboratory Ltd., Biogen, CSL Behring, Novo Nordisk, Pfizer, Inc., Takeda Pharmaceutical Co. Ltd., among others, hold the substantial market share in the Rare Hemophilia Factors market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client’s requirements
  • 3 months of analyst support